$Eli Lilly(LLY.US)Eli Lilly's newly launched oral weight-loss drug Foundayo showed moderate prescription data performance in its second week on the market, failing to replicate the explosive start of competitor Novo Nordisk's oral version of Wegovy back in the day, raising market doubts about whether this product can successfully catch up in the oral weight-loss drug race.

According to IQVIA prescription data cited by RBC Capital Markets analysts, Foundayo generated a total of 3,707 prescriptions in the U.S. during the second week of April. Although this number increased from 1,390 in its first week, it pales in comparison to the 18,410 prescriptions for Novo Nordisk's oral Wegovy in its second week on the market.

I still hope to adjust a bit more aggressively. I've been watching this stock for a long time, and the long-term entry point is basically here, but I still want the price to be a bit more suitable. Just wait patiently.